A growing body of proof suggests that oncogenic mutated epidermal growth factor receptor (EGFR) favors an MR to glycolysis, which is conceivably reversed via EGFR tyrosine-kinase inhibitors (TKIs), thereby inhibiting cancer cell growth. The gene discussed is EGFR; the disease is cancer.